Alkermes PLC shares ticked higher in the extended session Monday after the biotech company said the Food and Drug Adminstration approved its schizophrenia treatment Aristada. Alkermes shares rose 6.5% to $63.63. The company said the approval was based on data from a late-stage clinical study showing Aristada significantly reduced signs and symptoms of schizophrenia in patients after 12 weeks.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News